1-20 of 1387 Search Results for

oncolytic

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3560.
Published: 15 June 2022
.... Lamfers Background: The brain tumor glioblastoma (GBM) is one of the most aggressive forms of cancer. The dismal prognosis of these patients, with a median survival of less than 15 months despite maximal therapy makes the need for new therapeutic approaches urgent. Clinical trials employing oncolytic...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): LB537.
Published: 15 June 2022
...Deyin Guo; Fan Xing; Jingshu Xiao; Jiaming liang Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumor. Although oncolytic virus (OV) therapy has been proposed as a potential approach to treat GBM, the resistance is frequently observed because GBM cells...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5205.
Published: 15 June 2022
...Yanal Murad; Guoyu Liu; I-Fang Lee; Zahid Delwar; Dmitry Chouljenko; Will Liu; Jun Ding; Luke Bu; Ronghua Zhao; William Jia VG2025 is a genetically modified HSV-1 oncolytic virus (OV) wherein the transcription and translation of critical viral genes are regulated to enhance virus safety and promote...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1983.
Published: 15 June 2022
... targets and drug combinations in cancer treatment. We recently completed phase I/II testing of ONCOS-102, a GM-CSF-encoding oncolytic adenovirus (Ad5/3-D24-GMCSF), for therapeutic efficacy and capacity to remodel tumor micro-environment (TME) in combination with pembrolizumab (pem) in patients (pts...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 378.
Published: 15 June 2022
.... Oncolytic viruses (OVs) have garnered attention as anti-cancer adjuvants due to their potential for systemic delivery and ability to lyse tumor cells while leaving healthy cells unaffected. Clinical trials have been conducted testing the efficacy of OVs on diverse cancers. Although targeting distributed...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2048.
Published: 15 June 2022
.... In vitro and in vivo characterization of non-oncolytic engineered arenavirus vectors for cancer immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2048. ©...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3366.
Published: 15 June 2022
...Jia Yao; Svetlana Atasheva; Dmitry Shayakhmetov The increased cancer incidence and associated mortality call for the development of novel treatment modalities to address needs of cancer patients, which do not respond to existing therapies. Oncolytic viruses emerge as a new modality in cancer...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3572.
Published: 15 June 2022
... of effector T-cell tissue infiltration. Altering specific TME properties can reduce immune-suppression and improve anti-tumor immunity with abscopal effects. Oncolytic Virotherapy (OV) is a promising approach for cancer treatment. We evaluated the efficacy of the HSV-1 (VC2) vaccine strain for the treatment...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): CT155.
Published: 15 June 2022
...Kevin J. Harrington; Praveen K. Bommareddy; Mark R. Middleton; Joseph J. Sacco; Anna Olsson-Brown; Tze Y. Chan; Pablo Nenclares; Isla Leslie; Francesca Aroldi; Imran Saleem; Christoph M. Ahlers; Henry Castro; Robert S. Coffin Introduction: RP2 is a novel, enhanced potency oncolytic HSV1 which...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3501.
Published: 15 June 2022
... resistance. Immunostimulatory gene therapy using oncolytic viruses (OVs) has been developed as a new promising cancer therapy for its capacity to induce an anti-tumor immune response and sensitize the non-responding patients to checkpoint blockade therapy. Lokon adenoviruses (LOAds) are serotype 5/35...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3542.
Published: 15 June 2022
... MEM-288 pre-treatment generates a superior TIL product for more effective adoptive T cell therapy. Citation Format: Hong Zheng, Scott Antonia, Mark J. Cantwell, Xiaoqing Yu, Amer A. Beg. Oncolytic adenovirus encoding transgenes for IFN-beta and recombinant CD40 ligand promotes conventional...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3551.
Published: 15 June 2022
...Ryosuke Ono; Kosuke Takayama; Fuminori Sakurai; Hiroyuki Mizuguchi Oncolytic adenoviruses (OAds) are getting much attention as cancer immunotherapy agents. Almost all OAds are based on human adenovirus serotype 5 (Ad5) (OAd5). However, OAd5 has several drawbacks which possibly attenuate the anti...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 4184.
Published: 15 June 2022
...; Candelaria Gomez-Manzano Viroimmunotherapy aims to infect cancer cells to elicit anti-tumor immune responses. In clinical trials, glioma treatment with oncolytic viruses induced durable clinical responses in a small fraction of patients. To improve the percentage of responders, it is necessary to reshape...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 4193.
Published: 15 June 2022
...Bart Spiesschaert; Philipp Müller; Katharina Angerer; Krishna Das; Tobias Nolden; Carles Urbiola; Judy Ng; Fabian Heinemann; Birgit Stierstorfer; Patrik Erlmann; Guido Wollmann Introduction: Oncolytic viruses (OVs), which selectively replicate in and destroy tumor cells, form a highly promising...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): CT218.
Published: 15 June 2022
...Noelia Purroy; Nicholas Durham; Marc Phillips; Maureen M. Hattersley; Lindsey Jung; Diwakar Davar; Dmitriy Zamarin; Tanner M. Johanns; Igor Puzanov Background: Oncolytic viruses selectively infect tumors and activate antitumor immune responses via innate and adaptive pathways, leading...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2001.
Published: 15 June 2022
...-RGDOX, an oncolytic adenovirus based on Delta-24-RGD platform, which has demonstrated safety and a therapeutic benefit in different pediatric tumors, armed with the ligand of OX40. The binding of OX40 to OX40L leads to the co-stimulation of CD4 and CD8 cells, generating effector and memory T cells...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2053.
Published: 15 June 2022
...Svetlana Atasheva; Jia Yao; Dmitry Shayakhmetov Introduction: Oncolytic virotherapy represents a promising cancer treatment modality. One of the appeals of oncolytic virotherapy approaches is the capacity of viruses to change tumor microenvironment, frequently interpreted as de-polarization...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3559.
Published: 15 June 2022
... coronavirus infections induced complete remissions in lymphoma patients emphasized again the potential of cancer virotherapy. Infection of cancer cells with oncolytic viruses reshapes the tumor microenvironment by activating anti-viral and anti-tumor immunity. A phase 1 clinical trial using oncolytic...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3561.
Published: 15 June 2022
...So Young Yoo Here, we developed a novel oncolytic vaccinia virus (NOV) with the dual advantages of cancer selectivity and normal vessel reconstructive activity by replacing the viral thymidine kinase (vTk) and vaccinia growth factor (VGF) genes with genes encoding TNF-related apoptosis-inducing...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3562.
Published: 15 June 2022
...) capable of presenting tumor antigens to T cells that can expand and kill tumor cells. However, the tumor is a harsh environment for the adaptive immune system and many of the conditions needed for the establishment of an immune response are lacking. Oncolytic viral therapy presents an opportunity...